Interleukin-2 (IL-2) with 13-cis retinoic acid (RA) is more effective than IL-2 alone, as maintenance therapy in advanced cancer responsive to chemotherapy. Final result of a phase-II randomized trial. Proc Am Ass Cancer Res 2004: 45;1082. Abstract #4684.